Post Exposure Prophylaxis study (treated after exposure to the virus)
, M., arXiv.org, arXiv:2007.09477 (Preprint) (meta analysis - not included in the study count)
Efficacy of Hydroxych loroquine as Prophylaxis for Covid-19
Secondary analysis of Boulware et al.'s PEP trial and treatment delay-response data, confirming that HC
Q is effective when used early, p<0.01.
The effectiveness found is especially notable considering the limitations of the study. Treatment was relatively late, with enrollment up to
4 days after exposure, and an unspecified shipping delay. While the paper does not provide shipping details, the study protocol gives some detail allowing us to estimate the treatment delay as ~70 to 140 hours after exposure on average for the 1-4 days since enrollment specified in the paper (we will update this when authors respond to our request for details). There was only 75% medication adherence, including 16% who did not take the medication at all. The study relies on Internet surveys.
Meta studies are not included in the percentages or study count.
Please send us corrections, updates, or comments: